Target Validation Pathfinder Grant
The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance.
Alzheimer’s Research UK has developed two strategic initiatives to support the discovery of new therapeutics for dementia, covering preclinical target validation and early phase drug discovery.
The ARUK Drug Discovery Alliance (DDA) is a network of Drug Discovery Institutes (DDIs) embedded within the Universities of Cambridge, Oxford and University College London. The DDA will take advantage of new science in neurodegenerative diseases that cause dementia from within the academic Institutions and elsewhere and rapidly translate this to novel drug discovery projects and/or novel biomarkers with clinical or diagnostic utility.
The Dementia Consortium brings together ARUK, LifeArc and five pharmaceutical companies, Abbvie, Astex, Eisai, Lilly and MSD, to support drug discovery and pharmacological validation of novel molecular targets and expedite the development of new drugs for dementia. The Dementia Consortium provides funding, resources and expertise both to increase the number of, and capitalise upon, new drug targets emerging from across the academic sector. LifeArc is a life science medical research charity that helps bridge the gap between early stage research and commercial application through its dedicated drug discovery laboratories and 70+ scientists with expertise across early stage small molecule and antibody drug discovery. Any promising drug targets will then be made available to any of the Pharma partners.
There are both similarities and differences between the work of the Drug Discovery Alliance and the Dementia Consortium. ARUK wishes to see different options available for researchers and their individual preferences or circumstances.
It is recognised that researchers may have promising data / projects which are too preliminary to progress with either the Drug Discovery Alliance or the Dementia Consortium. The Target Validation Pathfinder grant scheme (TVPG) is designed to support translational research that shows potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance, but would benefit from funding for preliminary, early-stage target validation work or feasibility studies to establish the viability of an approach.
Duration: Up to 12 months.